来自官方财务报表的收入、利润与现金流历史。
Becton, Dickinson and Company 为全球医疗机构、医生、生命科学研究人员、临床实验室、制药行业和公众开发、制造和销售医疗用品、设备、实验室设备和诊断产品。它通过医疗必需品、互联护理、生物制药系统、介入和生命科学部门运营。它提供外周静脉（IV）和先进的外周导管、中心导管、急性透析导管、血管通路技术、血管护理和准备产品、无针静脉注射连接器和延长套件、封闭系统药物传输装置、危险药物检测、皮下注射器和针头、麻醉针头和托盘、肠内注射器和锐器处理系统； IV药物安全和输液治疗输送系统、药物配制工作流程系统、自动化药物配药和供应管理系统、信息学和分析以及药房自动化系统以及药物库存优化和跟踪系统；血流动力学监测系统；和预填充药物输送系统。它还提供标本和血液采集产品；自动化血液和结核病培养、分子检测、微生物鉴定和药物敏感性，以及快速诊断分析、微生物实验室自动化产品和平板培养基产品；荧光激活细胞分选仪和分析仪、抗体和试剂盒、试剂系统和单细胞基因表达分析解决方案，以及临床肿瘤学、免疫学和移植诊断/监测试剂和分析仪。它提供疝气和软组织修复、生物和生物可吸收移植物、生物外科等
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 | 2015-09-30 | 2014-09-30 | 2013-09-30 | 2012-09-30 | 2011-09-30 | 2010-09-30 | 2009-09-30 | 2008-09-30 | 2007-09-30 | 2006-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $20.8B | $21.8B | $20.2B | $19.4B | $18.9B | $19.1B | $16.1B | $17.3B | $16.0B | $12.1B | $12.5B | $10.3B | $8.4B | $8.1B | $7.7B | $7.6B | $7.1B | $7.0B | $7.1B | $6.4B | $5.7B |
| 毛利 | $9.6B | $9.9B | $9.1B | $8.2B | $8.5B | $8.6B | $6.8B | $8.3B | $7.3B | $6.0B | $6.0B | $4.7B | $4.3B | $4.2B | $4.0B | $4.0B | $3.7B | $3.7B | $3.6B | $3.3B | $2.9B |
| 毛利率% | 46.1% | 45.4% | 45.2% | 42.2% | 44.9% | 45.1% | 42.3% | 47.9% | 45.5% | 49.3% | 48.0% | 45.7% | 50.9% | 51.8% | 51.3% | 52.2% | 51.9% | 52.6% | 51.3% | 51.7% | 51.3% |
| 营业利润（EBIT） | $2.0B | $2.6B | $2.4B | $2.1B | $2.3B | $2.2B | $912M | $1.8B | $1.5B | $1.5B | $1.4B | $1.1B | $1.6B | $1.3B | $1.6B | $1.7B | $1.6B | $1.6B | $1.5B | $1.2B | $1.1B |
| 营业利润率% | 9.8% | 11.8% | 11.9% | 10.9% | 12.1% | 11.8% | 5.7% | 10.2% | 9.4% | 12.6% | 11.5% | 10.4% | 19.0% | 15.6% | 20.2% | 22.0% | 22.2% | 22.8% | 21.7% | 18.9% | 19.9% |
| 净利 | $941M | $1.7B | $1.7B | $1.5B | $1.8B | $2.1B | $874M | $1.2B | $311M | $1.1B | $976M | $695M | $1.2B | $1.3B | $1.2B | $1.3B | $1.3B | $1.2B | $1.1B | $890M | $752M |
| 净利润率 % | 4.5% | 7.7% | 8.5% | 7.7% | 9.4% | 10.9% | 5.4% | 7.1% | 1.9% | 9.1% | 7.8% | 6.8% | 14.0% | 16.1% | 15.2% | 16.8% | 18.5% | 17.6% | 15.9% | 14.0% | 13.1% |
| EBITDA | $3.9B | $5.0B | $4.8B | $4.4B | $4.4B | $4.4B | $3.1B | $4.1B | $3.9B | $2.6B | $2.6B | $2.0B | $2.2B | $1.8B | $2.1B | $2.2B | $2.1B | $2.1B | $2.1B | $1.8B | $1.6B |
| 每股收益（EPS） | $3.32 | $5.84 | $5.86 | $5.15 | $6.19 | $7.16 | $3.09 | $4.49 | $1.18 | $4.92 | $4.49 | $3.35 | $5.99 | $6.49 | $5.59 | $5.62 | $5.49 | $4.99 | $4.46 | $3.49 | $2.93 |
| 已发行股数 (M) | 275M | 287M | 291M | 288M | 287M | 292M | 282M | 275M | 265M | 224M | 218M | 208M | 198M | 199M | 209M | 226M | 240M | 247M | 253M | 255M | 257M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 BDX 交互式查看器。 /companies/us/BDX
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms